An evaluation of mogamulizumab for the treatment of peripheral T-cell lymphoma

Bibliography

• Ascani S, Zinzani PL, Gherlinzoni F, et al. Peripheral T-cell lymphomas. Clinico-pathologic study of 168 cases diagnosed according to the R.E.A.L. Classification. Ann Oncol 1997;8:583-92
   PubMed Web of Science ®Google Scholar
• Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin’s lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin’s Lymphoma Classification Project. Ann Oncol 1998;9:717-20
   PubMed Web of Science ®Google Scholar
• Vose J, Armitage J, Weisenburger D; International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008;26:4124-30
   PubMed Web of Science ®Google Scholar
• Lymphoma Study Group of Japanese Pathologists: the World Health Organization classification of malignant lymphomas in Japan: incidence of recently recognized entities. Pathol Int 2000;50:696-702
   PubMed Web of Science ®Google Scholar
• Nakamura S, Koshikawa T, Koike K, et al. Phenotypic analysis of peripheral T cell lymphoma among the Japanese. Acta Pathol Jpn 1993;43:396-412
   PubMedGoogle Scholar
• Aoki R, Karube K, Sugita Y, et al. Distribution of malignant lymphoma in Japan: analysis of 2260 cases, 2001–2006. Pathol Int 2008;58:174-82
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumors of haematopoietic and lymphoid tissues. IARC Press, Lyon, France; 2008
   Google Scholar
• National Comprehensive Cancer Network (NCCN). Non-Hodgkin’s lymphomas. NCCN clinical practice guidelines in oncology. v.1.2013. NCCN, Fort Washington, PA; 2013
   Google Scholar
• Coiffier B, Lepage E, Brière J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002;346:235-42
   PubMed Web of Science ®Google Scholar
• Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013;369:507-16
   PubMed Web of Science ®Google Scholar
• Sandlund JT, Pui CH, Santana VM, et al. Clinical features and treatment outcome for children with CD30+ large-cell non-Hodgkin’s lymphoma. J Clin Oncol 1994;12:895-8
   PubMed Web of Science ®Google Scholar
• Foss FM, Zinzani PL, Vose JM, et al. Peripheral T-cell lymphoma. Blood 2011;117:6756-67
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Mahadevan D, Cebula E, et al. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. J Clin Oncol 2014;32:44-50
   PubMed Web of Science ®Google Scholar
• Sonoda S, Li HC, Tajima K. Ethnoepidemiology of HTLV-1 related diseases: ethnic determinants of HTLV-1 susceptibility and its worldwide dispersal. Cancer Sci 2011;102:295-301
   PubMed Web of Science ®Google Scholar
• Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma: a report from the Lymphoma Study Group (1984–87). Br J Haematol 1991;79:428-37
   PubMed Web of Science ®Google Scholar
• Tsukasaki K, Utsunomiya A, Fukuda H, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemialymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol 2007;25:5458-64
   PubMed Web of Science ®Google Scholar
• Bazarbachi A, Plumelle Y, Carlos Ramos J, et al. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol 2010;28:4177-83
   PubMed Web of Science ®Google Scholar
• Utsunomiya A, Miyazaki Y, Takatsuka Y, et al. Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2001;27:15-20
   PubMed Web of Science ®Google Scholar
• Hishizawa M, Kanda J, Utsunomiya A, et al. Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study. Blood 2010;116:1369-76
   PubMed Web of Science ®Google Scholar
• Ishida T, Hishizawa M, Kato K, et al. Impact of graft-versus-host disease on allogeneic hematopoietic cell transplantation for adult T cell leukemia-lymphoma focusing on preconditioning regimens: nationwide retrospective study. Biol Blood Marrow Transplant 2013;19:1731-9
   PubMed Web of Science ®Google Scholar
• D’Ambrosio D, Iellem A, Bonecchi R, et al. Selective up-regulation of chemokine receptors CCR4 and CCR8 upon activation of polarized human type 2 Th cells. J Immunol 1998;161:5111-15
   PubMed Web of Science ®Google Scholar
• Iellem A, Mariani M, Lang R, et al. Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J Exp Med 2001;194:847-53
   PubMed Web of Science ®Google Scholar
• Mariani M, Lang R, Binda E, et al. Dominance of CCL22 over CCL17 in induction of chemokine receptor CCR4 desensitization and internalization on human Th2 cells. Eur J Immunol 2004;34:231-40
   PubMedGoogle Scholar
• Ishida T, Utsunomiya A, Iida S, et al. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. Clin Cancer Res 2003;9:3625-34
   PubMed Web of Science ®Google Scholar
• Jones D, O’Hara C, Kraus MD, et al. Expression pattern of T-cellassociated chemokine receptors and their chemokines correlates with specific subtypes of T-cell non-Hodgkin lymphoma. Blood 2000;96:685-90
   PubMed Web of Science ®Google Scholar
• Ishida T, Inagaki H, Utsunomiya A, et al. CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified. Clin Cancer Res 2004;10:5494-500
   PubMed Web of Science ®Google Scholar
• Yagi H, Seo N, Ohshima A, et al. Chemokine receptor expression in cutaneous T cell and NK/T-cell lymphomas: immunohistochemical staining and in vitro chemotactic assay. Am J Surg Pathol 2006;30:1111-19
   PubMed Web of Science ®Google Scholar
• Ishii T, Ishida T, Utsunomiya A, et al. Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma. Clin Cancer Res 2010;16:1520-31
   PubMed Web of Science ®Google Scholar
• Shinkawa T, Nakamura K, Yamane N, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 2003;278:3466-73
   PubMed Web of Science ®Google Scholar
• Yano H, Ishida T, Imada K, et al. Augmentation of antitumour activity of defucosylated chimeric anti-CCR4 monoclonal antibody in SCID mouse model of adult T-cell leukaemia/lymphoma using G-CSF. Br J Haematol 2008;140:586-9
   PubMed Web of Science ®Google Scholar
• Niwa R, Sakurada M, Kobayashi Y, et al. Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density. Clin Cancer Res 2005;11:2327-36
   PubMed Web of Science ®Google Scholar
• Niwa R, Shoji-Hosaka E, Sakurada M, et al. Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res 2004;64:2127-33
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Utsunomiya A, Tobinai K, et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol 2010;28:1591-8
   PubMed Web of Science ®Google Scholar
• Ishida T, Joh T, Uike N, et al. Defucosylated anti-CCR4monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol 2012;30:837-42
   PubMed Web of Science ®Google Scholar
• Ogura M, Ishida T, Hatake K, et al. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-CC chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol 2014;32:1157-63
   PubMed Web of Science ®Google Scholar
• Jo T, Ishida T, Takemoto S, et al. Randomized phase II study of mogamulizumab (KW-0761) plus VCAP-AMP-VECP (mLSG15) versus mLSG15 alone for newly diagnosed aggressive adult T-cell leukemia-lymphoma (ATL) [abstract 8506]. Presented at the 49th Annual Meeting of the American Society of Clinical Oncology; May 31 – June 4 2013; Chicago, USA
   Google Scholar
• Duvic M, Pinter-Brown L, Foss FM, et al. Correlation of target molecule expression and overall response in refractory cutaneous T-cell lymphoma patients dosed with Mogamulizumab (KW-0761), a monoclonal antibody directed against CC chemokine receptor type 4 (CCR4) [abstract 3697]. Presented at the 54th Annual Meeting of the American Society of Hematology; 8 – 11 December 2012; Atlanta, USA
   Google Scholar
• Waldmann TA. Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma. Oncogene 2007;26:3699-703
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zhang M, Ravetch JV, et al. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD2 monoclonal antibody, MEDI-507. Blood 2003;102:284-8
   PubMedGoogle Scholar
• Zhang Z, Zhang M, Goldman CK, et al. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H. Cancer Res 2003;63:6453-7
   PubMed Web of Science ®Google Scholar
• Ravandi F, Faderl S. Complete response in a patient with adult T-cell leukemia (ATL) treated with combination of alemtuzumab and pentostatin. Leuk Res 2006;30:103-5
   PubMed Web of Science ®Google Scholar
• Ishida T, Ito A, Sato F, et al. Stevens-Johnson syndrome associated with mogamulizumab treatment of adult T-cell leukemia/lymphoma. Cancer Sci 2013;104:647-50
   PubMed Web of Science ®Google Scholar
• Jacobs JF, Nierkens S, Figdor CG, et al. Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy? Lancet Oncol 2012;13:e32-42
   PubMed Web of Science ®Google Scholar
• Ishida T, Ueda R. Immunopathogenesis of lymphoma: focus on CCR4. Cancer Sci 2011;102:44-50
   PubMedGoogle Scholar